Described herein is method of making a multifunctional compound by starting with a H(OR).sub.nP(O)(OR.sub.h.sup.1).sub.2 and performed a series of reactions to form a functionalized phosphorous compound such as CF.sub.2CFCFY.sup.2(OR).sub.nP(O)(OQ).sub.2(VIIA) CF.sub.2X.sup.3CFCF(OR).sub.nP(O)(OQ).sub.2(VIIB), or CF.sub.2X.sup.3CHFC(O)(OR).sub.nP(O)(OH).sub.2(VIB) Where: R is a C1-C4 alkenyl group; X.sup.3 is F or (OR).sub.nP(O)(OQ).sub.2; n is 0 or 1; Y.sup.2 is F, Cl, Br, H, or a fluoroalkyl group comprising 1 to 3 carbon atoms, wherein the fluoroalkyl group optionally comprises at least one of an ether linkage, Cl, Br, or I; and Q is an alkyl group having 1 to 6 carbon atoms and optionally comprising at least one catenated ether linkage, Si(CH.sub.3).sub.3, Si(CH.sub.2CH.sub.3).sub.3, H, a metallic cation, or a quaternary ammonium cation can be disposed on a metal surface. Such compounds may be used in generating ionomeric polymers and/or applied onto metal substrates.

Radically polymerizable dental material, which contains at least one compound of Formula I:

##STR00001##

The material preferably additionally contains a radically polymerizable monomer, an initiator for the radical polymerization and filler. It is characterized by a low polymerization contraction stress.

The present invention concerns a method to access (E,Z)-7,9-dodecadienyl-1-acetate in two synthesis steps with excellent yields and selectivity greater than 70% by transformation of 2-hexenal into a novel intermediate, which is itself then transformed into (E,Z)-7,9-dodecandienyl-1-acetate.

The present patent application relates to a process for preparing cinacalcet or a pharmaceutically acceptable salt thereof, which comprises reacting 3-trifluoromethylbenzaldehyde having the following formula (II) with the phosphorus-comprising derivative having the following formula (III) in which R.sub.1 and R.sub.2, which may be identical or different, are each a (C.sub.1-C.sub.6)alkyl group. The present invention also relates to the phosphorus-comprising derivative having the formula (III), to the use thereof and to the process for preparing same. The present invention also relates to the phosphate salt of cinacalcet and to uses thereof.

A surface modified lithium titanate and preparation method thereof is provided. In the surface modified lithium titanate, the deactivating groups distributed on the surface of the lithium titanate are OPRRR, OP(OR)RR, OP(OR)(OR)R, and OP(OR)(OR)(OR), where R, R and R are identical or different C1C8 alkyl or alkenyl groups. The deactivating groups are bonded to the lithium titanate via a bond or a bridge. The exemplary surface modified lithium titanate can effectively lower its catalytic activity, reduce the gassing of lithium ion batteries, and therefore improve the high temperature storage and high temperature cycle performance of lithium titanate batteries. The exemplary preparation method is simple, has great repeatability, a low cost, low pollution to the environment, and is suitable for industrial production.

The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for C the treatment or prevention of conditions and diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, pathologic angiogenesis, heart failure and cardiac arrhythmias.

Provided is a method of manufacturing a high quality phosphonocrotonic acid derivative. The present invention is a method of manufacturing a compound represented by the following Formula (3) by reacting a compound represented by the following Formula (1) with a compound represented by the following Formula (2), which comprises a treatment process using an acid or base. [in the formula, R.sub.1 represents a C.sub.1-6 linear or branched alkyl group that may be substituted by a C.sub.6-10 aryl group, a C.sub.2-6 linear or branched alkenyl group that may be substituted by a C.sub.6-10 aryl group, a C.sub.2-6 linear or branched alkynyl group that may be substituted by a C.sub.6-10 aryl group, or a C.sub.6-10 aryl group, R.sub.2 represents a hydrogen atom, or a C.sub.1-6 linear or branched alkyl group that may be substituted by a C.sub.6-10 aryl group, R.sub.3 represents a C.sub.1-6 linear or branched alkyl group, a C.sub.6-10 aryl group, or a halogen atom, and X represents a halogen atom, and multiple R.sub.1s may be the same or different]. ##STR00001##

Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

Disclosed are novel conjugates and processes for the preparation thereof. A process for the preparation of alkene-or alkyne-phosohonothiolates and -phosphonates comprises the step of: reacting a compound of formula (I) with a thiol-containing molecule of formula (II) wherein represents an amino acid, a peptide, a protein, an antibody, a nucleotide, an oligonucleotide, a saccharide, a polysaccharide, a polymer, an optionally substituted C.sub.1-C.sub.8-alkyl, an optionally substituted phenyl, or an optionally substituted aromatic 5- or 6-membered heterocyclic system; resulting in a compound of formula (III).